John Arcaroli
Concepts (368)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Colorectal Neoplasms | 19 | 2018 | 749 | 2.630 |
Why?
| Xenograft Model Antitumor Assays | 21 | 2024 | 808 | 1.520 |
Why?
| Antineoplastic Agents | 17 | 2018 | 2046 | 1.410 |
Why?
| Drug Resistance, Neoplasm | 7 | 2016 | 752 | 1.080 |
Why?
| Benzodioxoles | 3 | 2012 | 106 | 1.040 |
Why?
| Quinazolines | 4 | 2012 | 243 | 1.030 |
Why?
| Camptothecin | 4 | 2016 | 110 | 0.910 |
Why?
| Receptor, Notch1 | 3 | 2015 | 62 | 0.870 |
Why?
| Aldehyde Dehydrogenase | 6 | 2017 | 101 | 0.870 |
Why?
| Mice, Nude | 16 | 2024 | 682 | 0.820 |
Why?
| Haplotypes | 4 | 2012 | 475 | 0.760 |
Why?
| Phosphatidylinositol 3-Kinases | 10 | 2018 | 361 | 0.720 |
Why?
| Wnt Signaling Pathway | 5 | 2024 | 170 | 0.650 |
Why?
| Gene Dosage | 3 | 2015 | 143 | 0.640 |
Why?
| Neutrophils | 13 | 2007 | 1210 | 0.630 |
Why?
| Pancreatic Neoplasms | 6 | 2024 | 880 | 0.620 |
Why?
| src-Family Kinases | 3 | 2017 | 95 | 0.600 |
Why?
| Amyloid Precursor Protein Secretases | 3 | 2014 | 79 | 0.600 |
Why?
| Endotoxemia | 9 | 2004 | 86 | 0.590 |
Why?
| Anilides | 2 | 2018 | 70 | 0.590 |
Why?
| Enzyme Inhibitors | 5 | 2016 | 827 | 0.590 |
Why?
| Protein Kinase Inhibitors | 9 | 2018 | 887 | 0.580 |
Why?
| Biomarkers, Tumor | 9 | 2018 | 1164 | 0.560 |
Why?
| Mice | 41 | 2024 | 16961 | 0.550 |
Why?
| Acute Lung Injury | 2 | 2011 | 280 | 0.530 |
Why?
| Pyridines | 4 | 2018 | 478 | 0.520 |
Why?
| Cell Line, Tumor | 21 | 2024 | 3186 | 0.510 |
Why?
| Receptors, Notch | 2 | 2015 | 84 | 0.510 |
Why?
| Tankyrases | 1 | 2016 | 14 | 0.510 |
Why?
| Drug Discovery | 1 | 2016 | 130 | 0.490 |
Why?
| Polymorphism, Genetic | 3 | 2007 | 637 | 0.470 |
Why?
| NF-kappa B | 13 | 2007 | 665 | 0.470 |
Why?
| 3' Untranslated Regions | 2 | 2012 | 138 | 0.460 |
Why?
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2014 | 84 | 0.450 |
Why?
| DNA Copy Number Variations | 1 | 2015 | 168 | 0.450 |
Why?
| Proto-Oncogene Proteins c-met | 1 | 2014 | 74 | 0.440 |
Why?
| Tetrahydronaphthalenes | 1 | 2013 | 30 | 0.420 |
Why?
| Valine | 1 | 2013 | 81 | 0.410 |
Why?
| Animals | 44 | 2024 | 35391 | 0.410 |
Why?
| Mitogen-Activated Protein Kinases | 7 | 2014 | 312 | 0.390 |
Why?
| Sepsis | 3 | 2007 | 575 | 0.370 |
Why?
| Lipopolysaccharides | 9 | 2007 | 877 | 0.360 |
Why?
| Signal Transduction | 17 | 2018 | 4931 | 0.360 |
Why?
| Proto-Oncogene Proteins | 8 | 2018 | 636 | 0.340 |
Why?
| Superoxide Dismutase | 3 | 2008 | 342 | 0.340 |
Why?
| Urokinase-Type Plasminogen Activator | 2 | 2007 | 29 | 0.340 |
Why?
| Cell Proliferation | 13 | 2024 | 2373 | 0.330 |
Why?
| Interleukins | 1 | 2011 | 241 | 0.320 |
Why?
| Hemorrhage | 6 | 2004 | 680 | 0.320 |
Why?
| Neoplasm Metastasis | 4 | 2016 | 611 | 0.320 |
Why?
| Class I Phosphatidylinositol 3-Kinases | 3 | 2014 | 81 | 0.300 |
Why?
| Heterografts | 3 | 2018 | 133 | 0.290 |
Why?
| HCT116 Cells | 4 | 2018 | 78 | 0.280 |
Why?
| Apoptosis | 11 | 2018 | 2492 | 0.280 |
Why?
| Carcinoma, Pancreatic Ductal | 2 | 2024 | 269 | 0.280 |
Why?
| SOXB1 Transcription Factors | 2 | 2018 | 57 | 0.270 |
Why?
| Azepines | 2 | 2018 | 88 | 0.260 |
Why?
| Promoter Regions, Genetic | 1 | 2011 | 1207 | 0.260 |
Why?
| Mutation | 3 | 2012 | 3717 | 0.260 |
Why?
| Benzimidazoles | 3 | 2013 | 162 | 0.260 |
Why?
| Immunoblotting | 5 | 2015 | 305 | 0.250 |
Why?
| beta Catenin | 3 | 2016 | 225 | 0.240 |
Why?
| Neutrophil Activation | 5 | 2003 | 80 | 0.240 |
Why?
| Receptors, Interleukin-1 | 1 | 2006 | 218 | 0.240 |
Why?
| Humans | 46 | 2024 | 129626 | 0.240 |
Why?
| TOR Serine-Threonine Kinases | 4 | 2018 | 398 | 0.230 |
Why?
| Oligonucleotide Array Sequence Analysis | 6 | 2015 | 756 | 0.230 |
Why?
| Pyrimidines | 2 | 2018 | 459 | 0.220 |
Why?
| Intracellular Signaling Peptides and Proteins | 2 | 2006 | 441 | 0.210 |
Why?
| Adrenergic alpha-Antagonists | 2 | 2002 | 33 | 0.210 |
Why?
| Proto-Oncogene Proteins c-akt | 8 | 2018 | 432 | 0.210 |
Why?
| Mice, Inbred BALB C | 10 | 2003 | 1250 | 0.210 |
Why?
| Colonic Neoplasms | 2 | 2016 | 242 | 0.210 |
Why?
| Female | 24 | 2018 | 68734 | 0.200 |
Why?
| Aged | 11 | 2016 | 22061 | 0.200 |
Why?
| Adrenergic alpha-Agonists | 1 | 2002 | 28 | 0.200 |
Why?
| Proto-Oncogene Proteins c-raf | 1 | 2002 | 45 | 0.200 |
Why?
| Genetic Predisposition to Disease | 1 | 2011 | 2274 | 0.200 |
Why?
| Neuroimmunomodulation | 1 | 2002 | 69 | 0.200 |
Why?
| ras Proteins | 3 | 2013 | 144 | 0.190 |
Why?
| Middle Aged | 12 | 2016 | 31136 | 0.190 |
Why?
| Adrenergic beta-Agonists | 1 | 2002 | 133 | 0.190 |
Why?
| Adrenergic beta-Antagonists | 2 | 2002 | 321 | 0.180 |
Why?
| Hemoptysis | 1 | 2000 | 35 | 0.170 |
Why?
| Polymorphism, Single Nucleotide | 4 | 2011 | 2060 | 0.170 |
Why?
| In Situ Hybridization, Fluorescence | 2 | 2012 | 313 | 0.170 |
Why?
| Adult | 11 | 2016 | 35599 | 0.170 |
Why?
| Head and Neck Neoplasms | 2 | 2016 | 544 | 0.160 |
Why?
| Carcinoma, Squamous Cell | 2 | 2016 | 627 | 0.160 |
Why?
| Male | 24 | 2016 | 63670 | 0.160 |
Why?
| Cytokines | 4 | 2005 | 2021 | 0.160 |
Why?
| Cell Transformation, Neoplastic | 2 | 2018 | 326 | 0.160 |
Why?
| DNA Topoisomerases, Type II | 2 | 2016 | 43 | 0.150 |
Why?
| Transplantation, Heterologous | 2 | 2016 | 192 | 0.150 |
Why?
| CDC2 Protein Kinase | 1 | 2018 | 31 | 0.150 |
Why?
| MAP Kinase Kinase Kinases | 2 | 2015 | 70 | 0.150 |
Why?
| Oncogene Proteins v-abl | 1 | 2017 | 5 | 0.140 |
Why?
| Cyclic AMP Response Element-Binding Protein | 4 | 2003 | 141 | 0.140 |
Why?
| Mitogen-Activated Protein Kinase Kinases | 3 | 2010 | 131 | 0.140 |
Why?
| p38 Mitogen-Activated Protein Kinases | 6 | 2007 | 276 | 0.140 |
Why?
| Case-Control Studies | 3 | 2011 | 3378 | 0.140 |
Why?
| Gene Expression Profiling | 4 | 2018 | 1687 | 0.140 |
Why?
| Dasatinib | 1 | 2017 | 54 | 0.140 |
Why?
| Proto-Oncogene Proteins p21(ras) | 5 | 2016 | 259 | 0.140 |
Why?
| Immunohistochemistry | 5 | 2017 | 1685 | 0.140 |
Why?
| Angiogenesis Inhibitors | 2 | 2018 | 219 | 0.130 |
Why?
| Intercellular Signaling Peptides and Proteins | 2 | 2015 | 374 | 0.130 |
Why?
| Adenocarcinoma | 2 | 2014 | 893 | 0.130 |
Why?
| Neovascularization, Pathologic | 2 | 2018 | 296 | 0.130 |
Why?
| Receptors, Cell Surface | 2 | 2012 | 381 | 0.130 |
Why?
| Phosphatidylinositol 3-Kinase | 1 | 2016 | 26 | 0.130 |
Why?
| Axin Protein | 1 | 2016 | 19 | 0.130 |
Why?
| Aurora Kinase A | 1 | 2016 | 54 | 0.130 |
Why?
| Corynebacterium | 1 | 2017 | 48 | 0.130 |
Why?
| Antigens, Neoplasm | 2 | 2016 | 308 | 0.130 |
Why?
| Corynebacterium Infections | 1 | 2017 | 40 | 0.130 |
Why?
| Cell Cycle | 5 | 2018 | 588 | 0.130 |
Why?
| Transcription Factor 7-Like 2 Protein | 1 | 2016 | 22 | 0.130 |
Why?
| Neoplasms, Experimental | 1 | 2017 | 170 | 0.130 |
Why?
| Neoplasms | 3 | 2016 | 2455 | 0.130 |
Why?
| Neoplastic Stem Cells | 2 | 2018 | 378 | 0.130 |
Why?
| Aged, 80 and over | 5 | 2014 | 7052 | 0.130 |
Why?
| Autophagy | 1 | 2018 | 266 | 0.120 |
Why?
| RNA, Messenger | 5 | 2016 | 2708 | 0.120 |
Why?
| Serrate-Jagged Proteins | 1 | 2015 | 27 | 0.120 |
Why?
| Genotype | 3 | 2012 | 1833 | 0.120 |
Why?
| Jagged-1 Protein | 1 | 2015 | 23 | 0.120 |
Why?
| RNA, Small Interfering | 2 | 2015 | 591 | 0.120 |
Why?
| Drug Synergism | 2 | 2014 | 370 | 0.120 |
Why?
| Gene Duplication | 1 | 2015 | 67 | 0.120 |
Why?
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2014 | 1560 | 0.120 |
Why?
| Retinaldehyde | 1 | 2015 | 5 | 0.120 |
Why?
| Pyrazoles | 1 | 2018 | 404 | 0.120 |
Why?
| HMGB1 Protein | 2 | 2007 | 49 | 0.120 |
Why?
| Acetaldehyde | 1 | 2015 | 17 | 0.120 |
Why?
| Pyrimidinones | 1 | 2015 | 102 | 0.120 |
Why?
| Chemokines | 5 | 2003 | 226 | 0.120 |
Why?
| Acridines | 1 | 2014 | 7 | 0.120 |
Why?
| Neoplasm Transplantation | 4 | 2016 | 256 | 0.110 |
Why?
| Chemokine CXCL2 | 4 | 2001 | 43 | 0.110 |
Why?
| Topoisomerase II Inhibitors | 1 | 2014 | 24 | 0.110 |
Why?
| Respiration, Artificial | 2 | 2011 | 613 | 0.110 |
Why?
| Pyridones | 1 | 2015 | 158 | 0.110 |
Why?
| Wnt Proteins | 1 | 2015 | 127 | 0.110 |
Why?
| Cell Cycle Proteins | 1 | 2018 | 584 | 0.110 |
Why?
| Benzazepines | 1 | 2014 | 39 | 0.110 |
Why?
| Calcium-Binding Proteins | 1 | 2015 | 213 | 0.110 |
Why?
| Gene Expression Regulation | 2 | 2007 | 2542 | 0.110 |
Why?
| Cell Growth Processes | 1 | 2013 | 52 | 0.110 |
Why?
| Cellular Senescence | 1 | 2015 | 181 | 0.100 |
Why?
| Disease Models, Animal | 4 | 2018 | 4078 | 0.100 |
Why?
| Insulin-Like Growth Factor Binding Protein 2 | 1 | 2012 | 8 | 0.100 |
Why?
| Tumor Suppressor Proteins | 1 | 2015 | 314 | 0.100 |
Why?
| DNA-Binding Proteins | 3 | 2016 | 1445 | 0.100 |
Why?
| Random Allocation | 1 | 2013 | 347 | 0.100 |
Why?
| Molecular Targeted Therapy | 1 | 2015 | 391 | 0.100 |
Why?
| Enzyme Activation | 6 | 2003 | 813 | 0.100 |
Why?
| Gene Knockdown Techniques | 1 | 2013 | 317 | 0.100 |
Why?
| Aldehyde Dehydrogenase, Mitochondrial | 3 | 2017 | 23 | 0.100 |
Why?
| Chemokine CXCL12 | 1 | 2012 | 79 | 0.100 |
Why?
| Receptors, CXCR4 | 1 | 2012 | 83 | 0.100 |
Why?
| Cyclosporine | 1 | 2013 | 263 | 0.100 |
Why?
| Linkage Disequilibrium | 2 | 2012 | 257 | 0.100 |
Why?
| Immunoprecipitation | 1 | 2012 | 157 | 0.090 |
Why?
| Lung | 8 | 2004 | 3938 | 0.090 |
Why?
| Lung Diseases | 3 | 2004 | 741 | 0.090 |
Why?
| Prognosis | 3 | 2015 | 3774 | 0.090 |
Why?
| Melanoma | 1 | 2018 | 730 | 0.090 |
Why?
| Hydroxamic Acids | 1 | 2011 | 88 | 0.090 |
Why?
| Drug Design | 1 | 2012 | 158 | 0.090 |
Why?
| Peroxidase | 2 | 2002 | 175 | 0.090 |
Why?
| Genetic Markers | 1 | 2012 | 336 | 0.090 |
Why?
| PTEN Phosphohydrolase | 1 | 2012 | 161 | 0.090 |
Why?
| Antibodies, Monoclonal, Humanized | 2 | 2013 | 757 | 0.090 |
Why?
| Sirolimus | 1 | 2012 | 270 | 0.090 |
Why?
| Genetic Association Studies | 1 | 2012 | 362 | 0.080 |
Why?
| Administration, Oral | 1 | 2012 | 787 | 0.080 |
Why?
| Histone Deacetylase Inhibitors | 1 | 2011 | 209 | 0.080 |
Why?
| Phosphorylation | 3 | 2018 | 1713 | 0.080 |
Why?
| Tumor Necrosis Factor-alpha | 4 | 2004 | 1202 | 0.080 |
Why?
| Cetuximab | 3 | 2016 | 94 | 0.080 |
Why?
| Cell Separation | 1 | 2010 | 317 | 0.080 |
Why?
| Membrane Proteins | 1 | 2015 | 1125 | 0.080 |
Why?
| Antibodies, Monoclonal | 1 | 2015 | 1366 | 0.070 |
Why?
| Gene Expression Regulation, Neoplastic | 4 | 2016 | 1336 | 0.070 |
Why?
| G2 Phase Cell Cycle Checkpoints | 2 | 2018 | 45 | 0.070 |
Why?
| Models, Statistical | 1 | 2012 | 625 | 0.070 |
Why?
| Genetic Variation | 2 | 2012 | 939 | 0.070 |
Why?
| Cells, Cultured | 6 | 2007 | 4084 | 0.070 |
Why?
| HT29 Cells | 2 | 2018 | 36 | 0.070 |
Why?
| Europe | 1 | 2007 | 363 | 0.070 |
Why?
| Gene Expression | 2 | 2003 | 1465 | 0.070 |
Why?
| Clinical Trials as Topic | 2 | 2015 | 1005 | 0.070 |
Why?
| ErbB Receptors | 3 | 2016 | 607 | 0.070 |
Why?
| Flow Cytometry | 1 | 2010 | 1159 | 0.060 |
Why?
| Genome, Human | 1 | 2008 | 394 | 0.060 |
Why?
| Thymine | 1 | 2006 | 14 | 0.060 |
Why?
| Cytosine | 1 | 2006 | 48 | 0.060 |
Why?
| Interleukin-1 Receptor-Associated Kinases | 1 | 2006 | 27 | 0.060 |
Why?
| Tumor Burden | 2 | 2018 | 286 | 0.060 |
Why?
| Phentolamine | 2 | 2002 | 14 | 0.060 |
Why?
| Translocation, Genetic | 1 | 2006 | 96 | 0.060 |
Why?
| Homozygote | 1 | 2006 | 195 | 0.060 |
Why?
| MAP Kinase Kinase 2 | 2 | 2002 | 28 | 0.060 |
Why?
| Inflammation Mediators | 2 | 2006 | 505 | 0.060 |
Why?
| Adolescent | 3 | 2011 | 20412 | 0.060 |
Why?
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2007 | 949 | 0.060 |
Why?
| Propranolol | 2 | 2002 | 50 | 0.060 |
Why?
| MicroRNAs | 1 | 2012 | 679 | 0.060 |
Why?
| Survival Analysis | 1 | 2008 | 1269 | 0.060 |
Why?
| Cell Nucleus | 2 | 2006 | 584 | 0.060 |
Why?
| MAP Kinase Kinase 1 | 2 | 2002 | 75 | 0.060 |
Why?
| Models, Biological | 2 | 2018 | 1724 | 0.060 |
Why?
| Spheroids, Cellular | 2 | 2016 | 77 | 0.060 |
Why?
| Introns | 1 | 2006 | 251 | 0.060 |
Why?
| Heat-Shock Proteins | 1 | 2005 | 136 | 0.060 |
Why?
| Mitogen-Activated Protein Kinase 3 | 2 | 2002 | 151 | 0.060 |
Why?
| Exons | 1 | 2006 | 342 | 0.060 |
Why?
| Bone Marrow Cells | 2 | 2003 | 302 | 0.060 |
Why?
| Neoplasm Invasiveness | 2 | 2016 | 481 | 0.060 |
Why?
| Cause of Death | 1 | 2006 | 395 | 0.050 |
Why?
| Positron-Emission Tomography | 2 | 2018 | 282 | 0.050 |
Why?
| Shock, Septic | 1 | 2006 | 209 | 0.050 |
Why?
| Oxidants | 1 | 2003 | 109 | 0.050 |
Why?
| Organoids | 1 | 2024 | 104 | 0.050 |
Why?
| Deoxycytidine | 1 | 2024 | 164 | 0.050 |
Why?
| Paclitaxel | 1 | 2024 | 217 | 0.050 |
Why?
| Ribosomal Protein S6 Kinases | 1 | 2002 | 21 | 0.050 |
Why?
| Brimonidine Tartrate | 1 | 2002 | 9 | 0.050 |
Why?
| Models, Genetic | 1 | 2005 | 593 | 0.050 |
Why?
| Phenylephrine | 1 | 2002 | 75 | 0.050 |
Why?
| RNA Interference | 2 | 2016 | 450 | 0.050 |
Why?
| Hydrogen Peroxide | 1 | 2003 | 317 | 0.050 |
Why?
| Quinoxalines | 1 | 2002 | 64 | 0.050 |
Why?
| Lung Neoplasms | 1 | 2015 | 2342 | 0.050 |
Why?
| Isoenzymes | 1 | 2003 | 301 | 0.050 |
Why?
| Transcription, Genetic | 2 | 2006 | 1418 | 0.050 |
Why?
| Protein-Tyrosine Kinases | 2 | 2002 | 431 | 0.050 |
Why?
| Cyclic AMP-Dependent Protein Kinases | 1 | 2002 | 133 | 0.050 |
Why?
| Membrane Glycoproteins | 1 | 2004 | 477 | 0.050 |
Why?
| Free Radical Scavengers | 1 | 2001 | 82 | 0.050 |
Why?
| Neoplasm Proteins | 3 | 2016 | 419 | 0.040 |
Why?
| High Mobility Group Proteins | 1 | 2000 | 42 | 0.040 |
Why?
| Imidazoles | 1 | 2001 | 234 | 0.040 |
Why?
| MAP Kinase Signaling System | 1 | 2002 | 313 | 0.040 |
Why?
| Neutropenia | 1 | 2000 | 137 | 0.040 |
Why?
| Transcriptome | 2 | 2016 | 876 | 0.040 |
Why?
| Nuclear Proteins | 2 | 2001 | 660 | 0.040 |
Why?
| Interleukin-1 | 2 | 2000 | 961 | 0.040 |
Why?
| Protein Processing, Post-Translational | 1 | 2002 | 457 | 0.040 |
Why?
| Adjuvants, Immunologic | 1 | 2000 | 221 | 0.040 |
Why?
| Trans-Activators | 1 | 2001 | 393 | 0.040 |
Why?
| M Phase Cell Cycle Checkpoints | 1 | 2018 | 24 | 0.040 |
Why?
| Colorado | 1 | 2008 | 4404 | 0.040 |
Why?
| 4-Aminobenzoic Acid | 1 | 2018 | 7 | 0.040 |
Why?
| Up-Regulation | 2 | 2016 | 840 | 0.040 |
Why?
| Biomarkers | 1 | 2008 | 3968 | 0.030 |
Why?
| Pneumonia | 1 | 2003 | 617 | 0.030 |
Why?
| Protein Transport | 1 | 2018 | 429 | 0.030 |
Why?
| Retinal Dehydrogenase | 1 | 2016 | 30 | 0.030 |
Why?
| Inhibitory Concentration 50 | 1 | 2016 | 86 | 0.030 |
Why?
| Hyaluronan Receptors | 1 | 2016 | 97 | 0.030 |
Why?
| Mice, Inbred C57BL | 4 | 2015 | 5455 | 0.030 |
Why?
| Blotting, Western | 2 | 2013 | 1206 | 0.030 |
Why?
| Protein Interaction Maps | 1 | 2016 | 42 | 0.030 |
Why?
| Tissue Array Analysis | 1 | 2016 | 55 | 0.030 |
Why?
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2016 | 117 | 0.030 |
Why?
| Papillomaviridae | 1 | 2016 | 114 | 0.030 |
Why?
| Drug Screening Assays, Antitumor | 1 | 2016 | 191 | 0.030 |
Why?
| Chromatin Immunoprecipitation | 1 | 2016 | 132 | 0.030 |
Why?
| Prospective Studies | 1 | 2007 | 7135 | 0.030 |
Why?
| S-Phase Kinase-Associated Proteins | 1 | 2015 | 20 | 0.030 |
Why?
| Diphenylamine | 1 | 2014 | 9 | 0.030 |
Why?
| Cadherins | 1 | 2016 | 190 | 0.030 |
Why?
| Iloprost | 1 | 2015 | 45 | 0.030 |
Why?
| Acid Phosphatase | 1 | 2014 | 20 | 0.030 |
Why?
| Young Adult | 1 | 2011 | 12455 | 0.030 |
Why?
| Rhodamines | 1 | 2014 | 18 | 0.030 |
Why?
| G2 Phase | 1 | 2014 | 36 | 0.030 |
Why?
| Cell Division | 1 | 2016 | 796 | 0.030 |
Why?
| Tumor Cells, Cultured | 1 | 2016 | 943 | 0.030 |
Why?
| Gene Expression Regulation, Enzymologic | 1 | 2016 | 285 | 0.030 |
Why?
| Inflammation | 1 | 2005 | 2750 | 0.030 |
Why?
| Sequence Analysis, RNA | 1 | 2016 | 427 | 0.030 |
Why?
| Epithelial-Mesenchymal Transition | 1 | 2016 | 201 | 0.030 |
Why?
| Tretinoin | 1 | 2015 | 130 | 0.030 |
Why?
| Benzamides | 1 | 2014 | 203 | 0.030 |
Why?
| Antigens, CD | 1 | 2016 | 487 | 0.030 |
Why?
| Retrospective Studies | 1 | 2011 | 14522 | 0.030 |
Why?
| Transfection | 1 | 2016 | 915 | 0.030 |
Why?
| Receptor, Notch2 | 1 | 2013 | 15 | 0.030 |
Why?
| Gonanes | 1 | 2013 | 27 | 0.030 |
Why?
| Alphapapillomavirus | 1 | 2013 | 39 | 0.030 |
Why?
| Receptors, CXCR | 1 | 2012 | 3 | 0.030 |
Why?
| Erlotinib Hydrochloride | 1 | 2012 | 70 | 0.020 |
Why?
| Cyclin D1 | 1 | 2012 | 63 | 0.020 |
Why?
| Disease-Free Survival | 1 | 2014 | 646 | 0.020 |
Why?
| Protein Binding | 1 | 2018 | 2124 | 0.020 |
Why?
| Tumor Suppressor Protein p53 | 1 | 2016 | 507 | 0.020 |
Why?
| Myeloid Cell Leukemia Sequence 1 Protein | 2 | 2003 | 40 | 0.020 |
Why?
| Active Transport, Cell Nucleus | 2 | 2003 | 113 | 0.020 |
Why?
| Computers | 1 | 2012 | 65 | 0.020 |
Why?
| Mice, Inbred C3H | 2 | 2004 | 272 | 0.020 |
Why?
| Maximum Tolerated Dose | 1 | 2012 | 193 | 0.020 |
Why?
| Niacinamide | 1 | 2012 | 75 | 0.020 |
Why?
| Phenylurea Compounds | 1 | 2012 | 88 | 0.020 |
Why?
| Tissue Distribution | 1 | 2012 | 315 | 0.020 |
Why?
| Mice, Knockout | 3 | 2003 | 2881 | 0.020 |
Why?
| Injections, Intraperitoneal | 2 | 2001 | 112 | 0.020 |
Why?
| Proto-Oncogene Proteins c-myc | 1 | 2012 | 131 | 0.020 |
Why?
| Proto-Oncogene Proteins c-bcl-2 | 2 | 2003 | 234 | 0.020 |
Why?
| Calcium Signaling | 1 | 2013 | 250 | 0.020 |
Why?
| Xanthine Oxidase | 2 | 2001 | 78 | 0.020 |
Why?
| Acute Disease | 2 | 2004 | 979 | 0.020 |
Why?
| United States | 1 | 2007 | 13871 | 0.020 |
Why?
| Cluster Analysis | 1 | 2011 | 482 | 0.020 |
Why?
| Nuclear Magnetic Resonance, Biomolecular | 1 | 2011 | 260 | 0.020 |
Why?
| Ligands | 1 | 2011 | 621 | 0.020 |
Why?
| Vascular Endothelial Growth Factor A | 1 | 2012 | 530 | 0.020 |
Why?
| Survival Rate | 1 | 2014 | 1872 | 0.020 |
Why?
| Models, Molecular | 1 | 2014 | 1491 | 0.020 |
Why?
| Computational Biology | 1 | 2013 | 596 | 0.020 |
Why?
| Tumor Microenvironment | 1 | 2012 | 627 | 0.020 |
Why?
| Dose-Response Relationship, Drug | 1 | 2012 | 2011 | 0.020 |
Why?
| Adiposity | 1 | 2012 | 504 | 0.020 |
Why?
| Cell Movement | 1 | 2011 | 948 | 0.020 |
Why?
| Mice, Transgenic | 2 | 2003 | 2128 | 0.020 |
Why?
| Calcium | 1 | 2013 | 1212 | 0.020 |
Why?
| Oxidative Stress | 2 | 2003 | 1266 | 0.020 |
Why?
| Magnetic Resonance Imaging | 1 | 2018 | 3394 | 0.020 |
Why?
| Neutrophil Infiltration | 1 | 2004 | 105 | 0.010 |
Why?
| Permeability | 1 | 2004 | 157 | 0.010 |
Why?
| Transcription Factor AP-1 | 1 | 2003 | 88 | 0.010 |
Why?
| Phosphotransferases | 1 | 2003 | 24 | 0.010 |
Why?
| Class Ib Phosphatidylinositol 3-Kinase | 1 | 2003 | 4 | 0.010 |
Why?
| bcl-Associated Death Protein | 1 | 2003 | 10 | 0.010 |
Why?
| Toll-Like Receptors | 1 | 2004 | 179 | 0.010 |
Why?
| Aconitate Hydratase | 1 | 2003 | 17 | 0.010 |
Why?
| Algorithms | 1 | 2010 | 1616 | 0.010 |
Why?
| JNK Mitogen-Activated Protein Kinases | 1 | 2003 | 161 | 0.010 |
Why?
| Reproducibility of Results | 1 | 2010 | 3080 | 0.010 |
Why?
| Lipid Peroxidation | 1 | 2003 | 151 | 0.010 |
Why?
| Mice, Mutant Strains | 1 | 2003 | 298 | 0.010 |
Why?
| Extracellular Space | 1 | 2003 | 120 | 0.010 |
Why?
| Metalloporphyrins | 1 | 2003 | 101 | 0.010 |
Why?
| Replication Protein C | 1 | 2001 | 4 | 0.010 |
Why?
| Tumor Necrosis Factor alpha-Induced Protein 3 | 1 | 2001 | 11 | 0.010 |
Why?
| Toll-Like Receptor 4 | 1 | 2004 | 264 | 0.010 |
Why?
| bcl-X Protein | 1 | 2001 | 42 | 0.010 |
Why?
| Biological Transport | 1 | 2003 | 404 | 0.010 |
Why?
| Cysteine Endopeptidases | 1 | 2001 | 68 | 0.010 |
Why?
| CREB-Binding Protein | 1 | 2001 | 27 | 0.010 |
Why?
| Protein Kinases | 1 | 2003 | 318 | 0.010 |
Why?
| Transcription Factor RelA | 1 | 2001 | 84 | 0.010 |
Why?
| Tungsten | 1 | 2001 | 30 | 0.010 |
Why?
| Animal Feed | 1 | 2001 | 50 | 0.010 |
Why?
| Proto-Oncogene Proteins c-fos | 1 | 2001 | 175 | 0.010 |
Why?
| Immune Sera | 1 | 2000 | 87 | 0.010 |
Why?
| Mitogen-Activated Protein Kinase 1 | 1 | 2001 | 184 | 0.010 |
Why?
| Organ Specificity | 1 | 2000 | 296 | 0.010 |
Why?
| Endotoxins | 1 | 2000 | 220 | 0.010 |
Why?
| Protein Biosynthesis | 1 | 2001 | 410 | 0.010 |
Why?
| Antioxidants | 1 | 2003 | 558 | 0.010 |
Why?
| Carrier Proteins | 1 | 2003 | 745 | 0.010 |
Why?
| Intubation, Intratracheal | 1 | 2000 | 242 | 0.010 |
Why?
| Peptides | 1 | 2001 | 926 | 0.010 |
Why?
| Treatment Outcome | 1 | 2010 | 10219 | 0.010 |
Why?
| Proteins | 1 | 2001 | 944 | 0.010 |
Why?
|
|
Arcaroli's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|